期刊文献+

中美化学仿制药参比制剂选择与管理的对比及启示 被引量:4

Comparison of the selection and management of reference medicinal products of chemical generic drugs in China and America
原文传递
导出
摘要 参比制剂是仿制药研发的标杆和基础。本文介绍了我国化学仿制药参比制剂的遴选工作背景、遴选原则和路径,美国参比制剂的确定及管理模式,通过分析中美两国参比制剂选择管理的异同,为进一步完善我国参比制剂遴选及管理工作提供参考。 Reference medicinal products are benchmarks and foundations for the research and development of generic drugs.This article introduced the work background,principle,and path of the selection of reference medicinal products of chemical generic drugs in China,the identification and management status of reference listed drugs in America,compared and analyzed the differences in the selection of reference preparations in China and the United States,to provide references for further improving the selection and management of reference medicinal products in China.
作者 游正坤 孙春萌 刘意林 郭志鑫 涂家生 YOU Zheng-kun;SUN Chun-meng;LIU Yi-lin;GUO Zhi-xin;TU Jia-sheng(National Medical Products Administration Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients,Department of Pharmaceuticals,School of Pharmacy,China Pharmaceutical University,Nanjing 210009,China;Center for Drug Evaluation,National Medical Products Administration,Beijing100022,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2022年第24期2458-2464,共7页 Chinese Journal of New Drugs
关键词 参比制剂 选择管理 仿制药 一致性评价 reference medicinal product selection management generic drug consistency evaluation
  • 相关文献

参考文献8

二级参考文献106

  • 1IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2011 [EB/OL]. [2012 - 04]. http://www, imsheahh, com/ims/Global/Content/Insights/IMS% 201nstitute% 20for% 20Healthcare% 20Informatics/IHI1_Medicines_in U. S_Report_2011. pdf.
  • 2WHEATON JJ. Generic Competition and Pharmaceutical Innovation-the Drug Price-Competition and Patent Term Restoration Act of 1984 [ J]. Catholic University Law Review, 1986, 35(2) : 433 -487.
  • 3LEWIS RA. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984[J]. J Contemp Health Law Policy, 1992, 8 (spring) : 361 - 378.
  • 4KARKI L. Review of FDA Law Related to Pharmaceutlcals: The Hatch- Waxman Act, Regulatory Amendments and Implications for Drug Patent Enforcement[J]. Journal of the Patent & Trademark Office Society, 2005, 87 : 602 - 620.
  • 5CAVES RE, WHINSTON MD, HURWITZ MA. Patent expiration, entry, and competition in the US pharmaceutical industry: an exploratory analysis [J]. Brookings Papers on Economic Activity, 1991, 7 (Special Issue on Microeconomics) : 1 - 48.
  • 6REIFFEN D, WARD MR. Generic drug industry dynamics[ J], Review of Economics and Statistics, 2005, 87 ( 1 ) : 37 - 49.
  • 7COOK A. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry [ EB/OL ]. [ 1998 -07 -01 ]. http ://www. cbo. gov/.
  • 8GATYAS G, IMS Health reports U.S. prescription sales grew 5.1 percent in 2009, to $ 300.3 Billion[ EB/OL]. [ 2010 - 04 - 01 ]. http ://www, imsheahh, com/portal/site/imsheahh/menuitem, a46c6d4df3db4b3d88f611019418c22a/? vgnextoid = d690a27e9dSb7210VgttVCM100000ed152-ca2RCRD & vgnextfmt = default.
  • 9U. S. HHS. FY 2008 Agency Financial Report [ EB/OL ]. [ 2008 - 08 - 26 ]. http ://www. hhs. gov/afr/2008sectili, pdf.
  • 10FEIN A. Generic Drug Profits: Too High or Appropriate Incentive? [N]. Gerson Lehrman Group News, 2008 -09 -11.

共引文献33

同被引文献22

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部